COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Zenflow, Inc.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 11, 2025 to Dec 11, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MER appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250007, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 395 Oyster Pt. Blvd., Suite 501, South San Francisco, CA, 94080. Recorded on P250007, decision dated Dec 11, 2025.
Device categories in this collection
Stent, Urethral, Prostatic, Permanent Or Semi-Permanent.
Changes described in PMA records
FDA’s recorded scope: The Zenflow Spring Implant and Delivery System is indicated for the treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) in men with prostatic urethral lengths between 25 and 45 mm and prostate sizes between 25 and 80 cc.
Dec 11, 2025Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.